Menu

Federal Contractor Misconduct Database (FCMD)

The federal government routinely awards contracts to companies with histories of misconduct, including contract fraud and other violations. POGO believes that providing this website will help to improve contracting decisions and increase public knowledge of how the government spends billions of taxpayer dollars each year. Read more…

Off-Label Marketing of Seroquel

AstraZeneca paid $520 million to resolve allegations that it illegally marketed anti-psychotic drug Seroquel for uses not approved as safe and effective by the U.S. Food and Drug Administration (FDA) between 2001 and 2006, and in so doing violated the False Claims Act. The U.S. government contended that AstraZeneca promoted the unapproved uses by improperly and unduly influencing the content of, and speakers in, company-sponsored continuing medical education programs and in academic studies and articles, in violation of the Anti-Kickback Statute. As part of the settlement, AstraZeneca entered into a five-year corporate integrity agreement with the Office of Inspector General of the Department of Health and Human Services.

Misconduct Type
Government Contract Fraud
Enforcement Agency
Justice
Contracting Party
Health and Human Services
Court Type
Civil
Disposition
Settlement
Date of Settlement Announcement
4/27/2010
Contractors Involved Penalty
Total
AstraZeneca PLC $520,000,000
Further Information Released
DOJ Press Release 4/27/2010

Federal Contractor Misconduct Database